Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission

NCT01843179 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01843179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01843179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2014
Completion date
January 31, 2014
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia